ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
LAPTM4B-35 protein as a potential therapeutic target in gastric cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.World journal of gastrointestinal oncology · 2024Review
- LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.Cell death & disease · 2024Article
- Role and mechanism of action of LAPTM4B in EGFR-mediated autophagy.Oncology letters · 2022Review
- Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer.BioMed research international · 2022Article
- LAPTM4B promotes the progression of bladder cancer by stimulating cell proliferation and invasion.Oncology letters · 2021Article
- Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma Treatment.Orthopaedic surgery · 2020Article
- Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma.Scientific reports · 2019Article
- LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.BMC cancer · 2019Article
- Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis.Journal of Cancer · 2018Article
- Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.Oncotarget · 2017Article
- Review
- Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to investigate lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) protein expression in gastric cancer and its clinical implications. LAPTM4B-35 protein expression in 652 gastric cancer specimens and matched adjacent non-cancerous tissues was evaluated by immunohistochemical staining. Subsequently, the relationship between LAPTM4B-35 protein expression, clinical pathological parameters, and prognosis of gastric cancer was determined. LAPTM4B-35 protein expression was significantly higher in gastric cancer tissue compared to adjacent non-cancerous tissues (P = 0.001). In total, 417 (63.96 %) of the 652 gastric cancer cases demonstrated high LAPTM4B-35 protein expression. Multiple regression analysis was performed to identify the factors related to lymph node metastasis. As a result, age, tumor number, primary tumor category, histological type, histological growth pattern, and LAPTM4B-35 protein expression were found to be significantly related to lymph node metastasis (P = 0.010, 0.001, 0.032, 0.001, 0.001, and 0.001, respectively). Survival analysis identified that LAPTM4B-35 protein expression was also an independent prognostic factor (P = 0.001). LAPTM4B-35 was highly expressed in gastric cancer and may be a potential target for the management of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.